Genome wide DNA copy number analysis of serous type ovarian carcinomas identifies genetic markers predictive of clinical outcome

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Engler, David A ^b   Gupta, Sumeet ^c   Growdon, Whitfield B ^a   Drapkin, Ronny I ^d   Nitta, Mai ^a   Sergent, Petra A ^a   Allred, Serena F ^b   Gross, Jenny ^f   Deavers, Michael T ^g   Kuo, Wen Lin ^e   Karlan, Beth Y ^f   Rueda, Bo R ^a   Orsulic, Sandra ^f   Gershenson, David M ^g   Birrer, Michael J ^a   Gray, Joe W ^e   Mohapatra, Gayatry ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM YOUNG UNIVERSITY   (United States)

^c WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^f CEDARS SINAI MEDICAL CENTER   (United States)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER GRADING; CANCER PATIENT; CLUSTER ANALYSIS; COHORT ANALYSIS; CONTROLLED STUDY; DNA MICROARRAY; FEMALE; GENE DOSAGE; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC MARKER; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CARCINOMA; OVERALL SURVIVAL; PREDICTION; PROGNOSIS; PROGRESSION FREE SURVIVAL; TUMOR DIFFERENTIATION; TUMOR SUPPRESSOR GENE; CANCER STAGING; CHROMOSOME MAP; COPY NUMBER VARIATION; CYSTADENOCARCINOMA; GENE EXPRESSION PROFILING; GENETICS; MIDDLE AGED; MORTALITY; OVARY TUMOR; PROSPECTIVE STUDY; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; CHROMOSOME MAPPING; CYSTADENOCARCINOMA, SEROUS; DNA COPY NUMBER VARIATIONS; FEMALE; GENE EXPRESSION PROFILING; GENETIC MARKERS; HUMANS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84857073155     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030996     Document Type: Article

References (106)

1. Ozols RF, Bookman MA, Connolly DC, Daly MB, Godwin AK, et al. (2004) Focus on epithelial ovarian cancer. Cancer Cell 5: 19-24.
2. Cannistra SA, (2004) Cancer of the ovary. N Engl J Med 351: 2519-2529.
3. Jemal A, Siegel R, Xu J, Ward E, (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
4. Dinh P, Harnett P, Piccart-Gebhart MJ, Awada A, (2008) New therapies for ovarian cancer: cytotoxics and molecularly targeted agents. Crit Rev Oncol Hematol 67: 103-112.
5. Balvert-Locht HR, Coebergh JW, Hop WC, Brolmann HA, Crommelin M, et al. (1991) Improved prognosis of ovarian cancer in The Netherlands during the period 1975-1985: a registry-based study. Gynecol Oncol 42: 3-8.
6. Agarwal R, Kaye SB, (2003) Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 3: 502-516.
7. FIGO Cancer Committee (1986) Staging announcement. Gynecol Oncol 25: 383-385.
8. Mutch DG, (2002) Surgical management of ovarian cancer. Semin Oncol 29: 3-8.
9. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, et al. (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21: 3194-3200.
10. du Bois A, Neijt JP, Thigpen JT, (1999) First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer-a new standard of care? Ann Oncol 10 (Suppl 1): 35-41.
11. Biagi JJ, Eisenhauer EA, (2003) Systemic treatment policies in ovarian cancer: the next 10 years. Int J Gynecol Cancer 13 (Suppl 2): 231-240.
12. Neijt JP, Engelholm SA, Tuxen MK, Sorensen PG, Hansen M, et al. (2000) Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 18: 3084-3092.
13. Sandercock J, Parmar MK, Torri V, Qian W, (2002) First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence. Br J Cancer 87: 815-824.
14. Perez RP, (1998) Cellular and molecular determinants of cisplatin resistance. Eur J Cancer 34: 1535-1542.
15. Niedner H, Christen R, Lin X, Kondo A, Howell SB, (2001) Identification of genes that mediate sensitivity to cisplatin. Mol Pharmacol 60: 1153-1160.
16. Li M, Balch C, Montgomery JS, Jeong M, Chung JH, et al. (2009) Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer. BMC Med Genomics 2: 34.
17. Seidman JD, Horkayne-Szakaly I, Haiba M, Boice CR, Kurman RJ, et al. (2004) The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol 23: 41-44.
18. Landen CN Jr, Birrer MJ, Sood AK, (2008) Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol 26: 995-1005.
19. Karst AM, Drapkin R, (2010) Ovarian cancer pathogenesis: a model in evolution. J Oncol 2010: 932371.
20. Bonome T, Lee JY, Park DC, Radonovich M, Pise-Masison C, et al. (2005) Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res 65: 10602-10612.
21. Zorn KK, Bonome T, Gangi L, Chandramouli GV, Awtrey CS, et al. (2005) Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res 11: 6422-6430.
22. Jazaeri AA, Awtrey CS, Chandramouli GV, Chuang YE, Khan J, et al. (2005) Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers. Clin Cancer Res 11: 6300-6310.
23. Etemadmoghadam D, deFazio A, Beroukhim R, Mermel C, George J, et al. (2009) Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. Clin Cancer Res 15: 1417-1427.
24. Haverty PM, Hon LS, Kaminker JS, Chant J, Zhang Z, (2009) High-resolution analysis of copy number alterations and associated expression changes in ovarian tumors. BMC Med Genomics 2: 21.
25. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, et al. (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712.
26. Baker VV, Borst MP, Dixon D, Hatch KD, Shingleton HM, et al. (1990) c-myc amplification in ovarian cancer. Gynecol Oncol 38: 340-342.
27. Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, et al. (1999) PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 21: 99-102.
28. Nanjundan M, Nakayama Y, Cheng KW, Lahad J, Liu J, et al. (2007) Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer. Cancer Res 67: 3074-3084.
29. Cheng KW, Lahad JP, Kuo WL, Lapuk A, Yamada K, et al. (2004) The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers. Nat Med 10: 1251-1256.
30. Park JT, Li M, Nakayama K, Mao TL, Davidson B, et al. (2006) Notch3 gene amplification in ovarian cancer. Cancer Res 66: 6312-6318.
31. Katoh M, (2008) Cancer genomics and genetics of FGFR2 (Review). Int J Oncol 33: 233-237.
32. Brown LA, Irving J, Parker R, Kim H, Press JZ, et al. (2006) Amplification of EMSY, a novel oncogene on 11q13, in high grade ovarian surface epithelial carcinomas. Gynecol Oncol 100: 264-270.
33. Kohler MF, Marks JR, Wiseman RW, Jacobs IJ, Davidoff AM, et al. (1993) Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. J Natl Cancer Inst 85: 1513-1519.
34. Singer G, Oldt R 3rd, Cohen Y, Wang BG, Sidransky D, et al. (2003) Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 95: 484-486.
35. Santin AD, Zhan F, Bellone S, Palmieri M, Cane S, et al. (2004) Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy. Int J Cancer 112: 14-25.
36. Yu Y, Xu F, Peng H, Fang X, Zhao S, et al. (1999) NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. Proc Natl Acad Sci U S A 96: 214-219.
37. Bruening W, Prowse AH, Schultz DC, Holgado-Madruga M, Wong A, et al. (1999) Expression of OVCA1, a candidate tumor suppressor, is reduced in tumors and inhibits growth of ovarian cancer cells. Cancer Res 59: 4973-4983.
38. Mok SC, Chan WY, Wong KK, Muto MG, Berkowitz RS, (1996) SPARC, an extracellular matrix protein with tumor-suppressing activity in human ovarian epithelial cells. Oncogene 12: 1895-1901.
39. Gorringe KL, Ramakrishna M, Williams LH, Sridhar A, Boyle SE, et al. (2009) Are there any more ovarian tumor suppressor genes? A new perspective using ultra high-resolution copy number and loss of heterozygosity analysis. Genes Chromosomes Cancer 48: 931-942.
40. Pinkel D, Segraves R, Sudar D, Clark S, Poole I, et al. (1998) High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat Genet 20: 207-211.
41. Arnold N, Hagele L, Walz L, Schempp W, Pfisterer J, et al. (1996) Overrepresentation of 3q and 8q material and loss of 18q material are recurrent findings in advanced human ovarian cancer. Genes Chromosomes Cancer 16: 46-54.
42. Sonoda G, Palazzo J, du Manoir S, Godwin AK, Feder M, et al. (1997) Comparative genomic hybridization detects frequent overrepresentation of chromosomal material from 3q26, 8q24, and 20q13 in human ovarian carcinomas. Genes Chromosomes Cancer 20: 320-328.
43. Gray JW, Suzuki S, Kuo WL, Polikoff D, Deavers M, et al. (2003) Specific keynote: genome copy number abnormalities in ovarian cancer. Gynecol Oncol 88: S16-21; discussion S22-14.
44. Caserta D, Benkhalifa M, Baldi M, Fiorentino F, Qumsiyeh M, et al. (2008) Genome profiling of ovarian adenocarcinomas using pangenomic BACs microarray comparative genomic hybridization. Mol Cytogenet 1: 10.
45. Kim SW, Kim JW, Kim YT, Kim JH, Kim S, et al. (2007) Analysis of chromosomal changes in serous ovarian carcinoma using high-resolution array comparative genomic hybridization: Potential predictive markers of chemoresistant disease. Genes Chromosomes Cancer 46: 1-9.
46. Nowee ME, Snijders AM, Rockx DA, de Wit RM, Kosma VM, et al. (2007) DNA profiling of primary serous ovarian and fallopian tube carcinomas with array comparative genomic hybridization and multiplex ligation-dependent probe amplification. J Pathol 213: 46-55.
47. Gorringe KL, Jacobs S, Thompson ER, Sridhar A, Qiu W, et al. (2007) High-resolution single nucleotide polymorphism array analysis of epithelial ovarian cancer reveals numerous microdeletions and amplifications. Clin Cancer Res 13: 4731-4739.
48. Sotiriou C, Piccart MJ, (2007) Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? Nat Rev Cancer 7: 545-553.
49. Straehle C, Cardoso F, Azambuja E, Dolci S, Meirsman L, et al. (2009) Better translation from bench to bedside: breakthroughs in the individualized treatment of cancer. Crit Care Med 37: S22-29.
50. Gabeau-Lacet D, Engler D, Gupta S, Scangas GA, Betensky RA, et al. (2009) Genomic profiling of atypical meningiomas associates gain of 1q with poor clinical outcome. J Neuropathol Exp Neurol 68: 1155-1165.
51. Zhang L, Huang J, Yang N, Liang S, Barchetti A, et al. (2006) Integrative genomic analysis of protein kinase C (PKC) family identifies PKCiota as a biomarker and potential oncogene in ovarian carcinoma. Cancer Res 66: 4627-4635.
52. Olshen AB, Venkatraman ES, Lucito R, Wigler M, (2004) Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 5: 557-572.
53. Korkola JE, Heck S, Olshen AB, Reuter VE, Bosl GJ, et al. (2008) In vivo differentiation and genomic evolution in adult male germ cell tumors. Genes Chromosomes Cancer 47: 43-55.
54. van de Wiel MA, van Wieringen WN, (2007) CGHregions: dimension reduction for array CGH data with minimal informatics loss. Cancer Informatics 2: 55-63.
55. Beroukhim R, Getz G, Nghiemphu L, Barretina J, Hsueh T, et al. (2007) Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A 104: 20007-20012.
56. Dimitriadou E, Hornik K, Leisch F, Meyer D, Weingessel A, (2006) e1071: Misc Functions of the Department of Statistics (e1071), TU Wien.
57. Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, et al. (2008) Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med 359: 2641-2650.
58. Farley J, Fuchiuji S, Darcy KM, Tian C, Hoskins WJ, et al. (2009) Associations between ERBB2 amplification and progression-free survival and overall survival in advanced stage, suboptimally-resected epithelial ovarian cancers: a Gynecologic Oncology Group Study. Gynecol Oncol 113: 341-347.
59. Griffiths CT, (1975) Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 42: 101-104.
60. Krag KJ, Canellos GP, Griffiths CT, Knapp RC, Parker LM, et al. (1989) Predictive factors for long-term survival in patients with advanced ovarian cancer. Gynecol Oncol 34: 88-93.
61. Ramaswamy S, Golub TR, (2002) DNA microarrays in clinical oncology. J Clin Oncol 20: 1932-1941.
62. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, et al. (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100: 8418-8423.
63. Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, et al. (2006) Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 10: 529-541.
64. Spentzos D, Levine DA, Ramoni MF, Joseph M, Gu X, et al. (2004) Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol 22: 4700-4710.
65. Bonome T, Levine DA, Shih J, Randonovich M, Pise-Masison CA, et al. (2008) A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer Res 68: 5478-5486.
66. Berchuck A, Iversen ES, Luo J, Clarke JP, Horne H, et al. (2009) Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcome. Clin Cancer Res 15: 2448-2455.
67. Yoshihara K, Tajima A, Komata D, Yamamoto T, Kodama S, et al. (2009) Gene expression profiling of advanced-stage serous ovarian cancers distinguishes novel subclasses and implicates ZEB2 in tumor progression and prognosis. Cancer Sci 100: 1421-1428.
68. Bell D, Berchuck A, Birrer M, Chien J, Cramer DW, et al. (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474: 609-615.
69. Cuenda A, (2000) Mitogen-activated protein kinase kinase 4 (MKK4). Int J Biochem Cell Biol 32: 581-587.
70. Yamada SD, Hickson JA, Hrobowski Y, Vander Griend DJ, Benson D, et al. (2002) Mitogen-activated protein kinase kinase 4 (MKK4) acts as a metastasis suppressor gene in human ovarian carcinoma. Cancer Res 62: 6717-6723.
71. Parsons DW, Wang TL, Samuels Y, Bardelli A, Cummins JM, et al. (2005) Colorectal cancer: mutations in a signalling pathway. Nature 436: 792.
72. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, et al. (2007) Patterns of somatic mutation in human cancer genomes. Nature 446: 153-158.
73. Kan Z, Jaiswal BS, Stinson J, Janakiraman V, Bhatt D, et al. (2010) Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 466: 869-873.
74. Cazillis M, Bringuier AF, Delautier D, Buisine M, Bernuau D, et al. (2004) Disruption of MKK4 signaling reveals its tumor-suppressor role in embryonic stem cells. Oncogene 23: 4735-4744.
75. Lefebvre V, Li P, de Crombrugghe B, (1998) A new long form of Sox5 (L-Sox5), Sox6 and Sox9 are coexpressed in chondrogenesis and cooperatively activate the type II collagen gene. Embo J 17: 5718-5733.
76. Huang DY, Lin YT, Jan PS, Hwang YC, Liang ST, et al. (2008) Transcription factor SOX-5 enhances nasopharyngeal carcinoma progression by down-regulating SPARC gene expression. J Pathol 214: 445-455.
77. Schuldiner O, Eden A, Ben-Yosef T, Yanuka O, Simchen G, et al. (1996) ECA39, a conserved gene regulated by c-Myc in mice, is involved in G1/S cell cycle regulation in yeast. Proc Natl Acad Sci U S A 93: 7143-7148.
78. Ju W, Yoo BC, Kim IJ, Kim JW, Kim SC, et al. (2009) Identification of genes with differential expression in chemoresistant epithelial ovarian cancer using high-density oligonucleotide microarrays. Oncol Res 18: 47-56.
79. Zhou W, Feng X, Li H, Wang L, Li H, et al. (2007) Functional evidence for a nasopharyngeal carcinoma-related gene BCAT1 located at 12p12. Oncol Res 16: 405-413.
80. Yoshikawa R, Yanagi H, Shen CS, Fujiwara Y, Noda M, et al. (2006) ECA39 is a novel distant metastasis-related biomarker in colorectal cancer. World J Gastroenterol 12: 5884-5889.
81. Liu P, Wang Y, Vikis H, Maciag A, Wang D, et al. (2006) Candidate lung tumor susceptibility genes identified through whole-genome association analyses in inbred mice. Nat Genet 38: 888-895.
82. Bos JL, (1988) The ras gene family and human carcinogenesis. Mutat Res 195: 255-271.
83. Johnson L, Mercer K, Greenbaum D, Bronson RT, Crowley D, et al. (2001) Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 410: 1111-1116.
84. Dinulescu DM, Ince TA, Quade BJ, Shafer SA, Crowley D, et al. (2005) Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med 11: 63-70.
85. Sarkisian CJ, Keister BA, Stairs DB, Boxer RB, Moody SE, et al. (2007) Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis. Nat Cell Biol 9: 493-505.
86. Farley J, Smith LM, Darcy KM, Sobel E, O'Connor D, et al. (2003) Cyclin E expression is a significant predictor of survival in advanced, suboptimally debulked ovarian epithelial cancers: a Gynecologic Oncology Group study. Cancer Res 63: 1235-1241.
87. Ohtsubo M, Theodoras AM, Schumacher J, Roberts JM, Pagano M, (1995) Human cyclin E, a nuclear protein essential for the G1-to-S phase transition. Mol Cell Biol 15: 2612-2624.
88. Resnitzky D, Hengst L, Reed SI, (1995) Cyclin A-associated kinase activity is rate limiting for entrance into S phase and is negatively regulated in G1 by p27Kip1. Mol Cell Biol 15: 4347-4352.
89. Kawamura K, Izumi H, Ma Z, Ikeda R, Moriyama M, et al. (2004) Induction of centrosome amplification and chromosome instability in human bladder cancer cells by p53 mutation and cyclin E overexpression. Cancer Res 64: 4800-4809.
90. Nakayama N, Nakayama K, Shamima Y, Ishikawa M, Katagiri A, et al. (2010) Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer. Cancer 116: 2621-2634.
91. Lin CQ, Singh J, Murata K, Itahana Y, Parrinello S, et al. (2000) A role for Id-1 in the aggressive phenotype and steroid hormone response of human breast cancer cells. Cancer Res 60: 1332-1340.
92. Schoppmann SF, Schindl M, Bayer G, Aumayr K, Dienes J, et al. (2003) Overexpression of Id-1 is associated with poor clinical outcome in node negative breast cancer. Int J Cancer 104: 677-682.
93. Qian Y, Chen X, (2008) ID1, inhibitor of differentiation/DNA binding, is an effector of the p53-dependent DNA damage response pathway. J Biol Chem 283: 22410-22416.
94. Schindl M, Schoppmann SF, Strobel T, Heinzl H, Leisser C, et al. (2003) Level of Id-1 protein expression correlates with poor differentiation, enhanced malignant potential, and more aggressive clinical behavior of epithelial ovarian tumors. Clin Cancer Res 9: 779-785.
95. Boise LH, Gonzalez-Garcia M, Postema CE, Ding L, Lindsten T, et al. (1993) bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74: 597-608.
96. Chipuk JE, Fisher JC, Dillon CP, Kriwacki RW, Kuwana T, et al. (2008) Mechanism of apoptosis induction by inhibition of the anti-apoptotic BCL-2 proteins. Proc Natl Acad Sci U S A 105: 20327-20332.
97. Williams J, Lucas PC, Griffith KA, Choi M, Fogoros S, et al. (2005) Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease. Gynecol Oncol 96: 287-295.
98. Iwabuchi H, Sakamoto M, Sakunaga H, Ma YY, Carcangiu ML, et al. (1995) Genetic analysis of benign, low-grade, and high-grade ovarian tumors. Cancer Res 55: 6172-6180.
99. Tanner MM, Grenman S, Koul A, Johannsson O, Meltzer P, et al. (2000) Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer. Clin Cancer Res 6: 1833-1839.
100. Lin B, White JT, Wu J, Lele S, Old LJ, et al. (2009) Deep depletion of abundant serum proteins reveals low-abundant proteins as potential biomarkers for human ovarian cancer. Proteomics Clin Appl 3: 853-861.
101. Clauss A, Ng V, Liu J, Piao H, Russo M, et al. (2010) Overexpression of elafin in ovarian carcinoma is driven by genomic gains and activation of the nuclear factor kappaB pathway and is associated with poor overall survival. Neoplasia 12: 161-172.
102. Jiang C, Ito M, Piening V, Bruck K, Roeder RG, et al. (2004) TIP30 interacts with an estrogen receptor alpha-interacting coactivator CIA and regulates c-myc transcription. J Biol Chem 279: 27781-27789.
103. Peterson D, Lee J, Lei XC, Forrest WF, Davis DP, et al. (2010) A chemosensitization screen identifies TP53RK, a kinase that restrains apoptosis after mitotic stress. Cancer Res 70: 6325-6335.
104. Colland F, Jacq X, Trouplin V, Mougin C, Groizeleau C, et al. (2004) Functional proteomics mapping of a human signaling pathway. Genome Res 14: 1324-1332.
105. Feller SM, Lewitzky M, (2006) Potential disease targets for drugs that disrupt protein- protein interactions of Grb2 and Crk family adaptors. Curr Pharm Des 12: 529-548.
106. Kuo KT, Guan B, Feng Y, Mao TL, Chen X, et al. (2009) Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas. Cancer Res 69: 4036-4042.